Skip to main content

Table 3 Multivariate analysis of prognostic factors for 272 patients with stage III NPC

From: Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up

Variables

LRFS

DMFS

DFS

OS

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

Age (≤ 43 vs. > 43, year)

1.378 (0.884–2.148)

0.157

1.946 (1.161–3.264)

0.012

Smoking (yes vs. no)

0.728 (0.452–1.172)

0.192

0.578 (0.336–0.996)

0.048

Alcohol (yes vs. no)

0.643 (0.369–1.121)

0.120

0.872 (0.506–1.502)

0.621

0.839 (0.462–1.522)

0.563

 N classification (N0-1 vs. N2)

1.910 (0.930-3.920)

0.078

1.683 (0.972–2.916)

0.063

1.722 (1.115–2.657)

0.014

1.629 (0.996–2.665)

0.052

CCT (yes vs. no)

1.737 (0.834-3.617)

0.140

1.431 (0.808–2.535)

0.219

1.661 (1.064–2.594)

0.026

1.876 (1.141–3.083)

0.013

EBV DNA (< 2000 vs. ≥ 2000)

1.664 (0.713-3.883)

0.239

  1. NPC, nasopharyngeal carcinoma; HR, hazard ratio; CI, confidence interval; LRFS, locoregional-free survival; DMFS, distant metastasis-free survival; DFS, disease-free survival; OS, overall survival; CCT, concurrent chemotherapy; EBV, Epstein–Barr virus